Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
23 Settembre 2024 - 2:00PM
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a
life sciences company developing precision genetic medicines for
neuromuscular and cardiac diseases, today announced that Bo Cumbo,
President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer,
will participate in a fireside chat at Chardan’s 8th Annual Genetic
Medicines Conference on Monday, September 30, 2024, at 11:00 am ET.
A live webcast of the fireside chat will be
available on the Events page of the Investors section of the
Company website or by clicking here. A webcast replay will be
archived for 30 days on the Events page.
Institutional investors interested in meeting
with management during the conferences may reach out to their
Chardan representatives.
About Solid BiosciencesSolid
Biosciences is a precision genetic medicine company focused on
advancing a portfolio of gene therapy candidates including SGT-003
for the treatment of Duchenne muscular dystrophy (Duchenne),
SGT-501 for the treatment of catecholaminergic polymorphic
ventricular tachycardia (CPVT), AVB-401 for the treatment of
BAG3-mediated dilated cardiomyopathy, and additional assets for the
treatment of fatal cardiac diseases. Solid is advancing its diverse
pipeline across rare neuromuscular and cardiac diseases, bringing
together experts in science, technology, disease management, and
care. Patient-focused and founded by those directly impacted,
Solid’s mandate is to improve the daily lives of patients living
with these devastating diseases. For more information, please visit
www.solidbio.com.
Solid Biosciences Investor
Contact:Nicole AndersonDirector, Investor Relations and
Corporate CommunicationsSolid Biosciences
Inc.investors@solidbio.com
Media Contact:Glenn SilverFINN
Partnersglenn.silver@finnpartners.com
Grafico Azioni Solid Biosciences (NASDAQ:SLDB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Solid Biosciences (NASDAQ:SLDB)
Storico
Da Dic 2023 a Dic 2024